Evidence map›Paper›PMID 34185142›Full record

ArticleJournal of cancer research and clinical oncology2022

Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region.

Hidetaka Uramoto, Tomoya Takiguchi, Tomonobu Koizumi, Azusa Tanimoto, Ryuji Hayashi, Yozo Nakazawa, Ken-Ichi Ito, Mitsutoshi Nakada, Yasuo Hirono, Yoshikazu Nishino and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hidetaka UramotoDepartment of Thoracic Surgery, Kanazawa Medical University, Kahoku, Japan. hidetaka@kanazawa-med.ac.jp.ORCID http://orcid.org/0000-0003-4451-4225
Tomoya TakiguchiDepartment of Epidemiology and Public Health, Kanazawa Medical University, Kahoku, Japan.
Tomonobu KoizumiDepartment of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Japan.
Azusa TanimotoDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Ryuji HayashiDepartment of Clinical Oncology, Toyama University Hospital, Toyama, Japan.
Yozo NakazawaDepartment of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Ken-Ichi ItoDivision of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Mitsutoshi NakadaDepartment of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Yasuo HironoCancer Care Promotion Center, University of Fukui Hospital, Fukui, Japan.
Yoshikazu NishinoDepartment of Epidemiology and Public Health, Kanazawa Medical University, Kahoku, Japan.
Seiji YanoDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant pleural mesothelioma (MPM) is a major occupational and environmental neoplasm. The purpose of this study was to validate the clinical and epidemiological factors, diagnosis, and initial treatment among MPM patients in the Hokushin region.

methodsWe surveyed retrospective data from 152,921 cancer patients in 22 principal hospitals.

resultsA total of 166 MPM cases were newly diagnosed. These patients consisted of 136 men and 30 women, with a median age of 69 years. We estimated the incidence rate for MPM to be 0.55 cases per 100,000 person-years in this study. The ratio per 100,000 population-years was 0.39 in Fukui, 0.60 in Ishikawa, 1.02 in Toyama and 0.35 in Nagano. Forty-five patients were discovered when diagnosed incidentally in patients under observations for other diseases. Forty-six cases were diagnosed as localized disease, while 13 had accompanying regional lymph node metastasis. Furthermore, 44 cases showed infiltration into adjacent organs. A histo-cytological diagnosis was made in 164 cases (98.8%). A surgical approach, chemotherapy, and radiotherapy were performed for 33, 88, and 6 patients, respectively, while 44 patients (26.5%) received best supportive care. Multimodality therapy was conducted in just 3.0% of the MPM patients

conclusionMPM has a tragically rapid progression if discovered under observations for other diseases. Workers in health-related fields should be on high alert for aggressive MPM. Better evaluation and multi-disciplinary approaches to MPM in these regions are needed to optimize multimodality therapy.

Indexed as

Lung NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsAgedFemaleHumansIncidenceMaleRetrospective StudiesCancer registrationCancer screeningGanpro databaseHokushin regionMalignant pleural mesothelioma

Identifiers

PMID34185142
PMCPMC11801112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.